

Robert Amdur, MD


I do not have any financial or nonfinancial interests in any companies or products that I will discuss during this session

2


4

6

1



The normal thyroid: Cancer of the Parafollicular C Cell is called MEDULLARY carcinoma Cancer of the Follicular cell called "Thyroid Carcinom and is subclassified by Degree of Differentiation: - WELL Differentiated: "Differentiated Thyroid Carcinoma" DTC - MODERATELY Differentiated: "Insular Carcinoma" POORLY Differentiated: "Anaplastic" Carcinoma Follicular cell makes THYROID HORMONES - T3 (Trijodothyronine, Cytomel); used by tissues but not stable in blood T4 (Levothyroxine, Synthroid): stable in serum and converted to T3 in tissues



I-131 Therapy for Thyroid Cancer Cancer of Parafollicular C cell (Medullary Ca.) Cancer of the Follicular Cell I-131 is only curative for Well Differentiated Thyroid Carcinoma because it's the only cancer subtype Well Differentiated (DTC) that retains the function of normal Follicular cells Poorly Differentiated (Insular) that concentrate lodine a lot more than other tissues to make T3/4 where the 3 and 4 are the Undifferentiated (Anaplastic) number of lodine atoms per hormone moleci The remainder of this presentation will be limited to treatment of DTC

Subtypes of (Well) Differentiated Thyroid Carcinoma (DTC)


When is "capsular invasion" discussed and important?

The 2 main subtypes of DTC are:

- Papillary
- Follicular

7

Can both of these subtypes be diagnosed by Fine Needle Aspirate (FNA)?



Confusing that "Follicular" is used 3 ways in classifying Thyroid Cancer

- 1. Cell of Origin of thyroid cancer: Follicular Cell vs Para Follicular C Cell (Medullary Ca)
- 2. Subtype of (Well) Differentiated Carcinioma of Follicle Cell origin Papillary Carcinioma (PTC)

Follicular Carcinoma

3. Subtype of Papillary Thyroid Carcinoma (PTC)

Classic histology Follicular Variant Oncocytic Variant

Tall Cell Hobnail - Unfavorable Variants

90% of Thyroid Cancer cases are Papillary or Follicular DTC Does Papillary vs Follicular matter for treatment decisions?





It's reasonable to say NO

8

It does'nt change I-131 decisions

There's controversy about central node dissection

9 10

Does the subtype of Papillary DTC change I-131 decisions?

Subtype of Papillary Thyroid Carcinoma (PTC)

Classic
Follicular Variant
Oncocytic Variant
Diffuse Sclerosing

11

Tall Cell Variant
Hobnail Variant

No difference in management of Classic, Follicular, and Oncocytic

Most consider an UNFAVORABLE VARIANT an independent indication for I-131 and higher dose category regardless of stage

Where does <u>Hurthle Cell</u> Thyroid Cancer fit in these guidelines?

Hurthle Cell Thyroid Cancer



12

Hurthle Cell = Oncocyte






Current debates are:

- Is Hurthle Cell Ca a subtype of Follicular Ca, or a unique entity?
- Does Hurthle Cell Ca have a worse prognosis than standard DTC?

2017 PMID 25730603
Favorable Outcome of Hurthle Cell Carcinoma of the Thyroid Treated With Total Thyroidectomy, Radioiodine, and Selective Use of External-Beam Radiotherapy

Proc Totalway \$151 Behort J. Andr. \$162** For Jr. Dev. \$162** Extend Co. \$162** Andr. \$162** For Jr. Ones \$162** Andr. \$162**

I treat Hurthle Cell Carcinoma like an Unfavorable Variant of DTC with 100-200 mCi I-131 based on risk factors



Total Thyroidectomy + Removal of all visible tumor and positive nodes, is required before considering adjuvant tx

Thyroid Cancer is PATHOLOGICALY STAGED

I-131 less effective if > 1cc of normal gland remaining due to the remant concentrating most of the I-131

Risk of injury to esophagus, larynx, RLN is higher from I-131 with large thyroid remant

Never want to treat gross dz with I-131 because cure rate is a lot higher if visible tumor removed surgically

13 14


Do we expect our surgical colleagues to ELECTIVELY DISSECT the lateral node stations (L2-4) as they would for other head and neck cancers?




No.
With Thyroid Cancer, Elective Neck Dissection is NOT done for L2,3,4,or 5 because I-131 is good at eliminating micro residual tumor.
(There's controversy about Elective Dissection of L6)


YES, dissect any neck station with visible positive node by imaging preop or on inspection at the time of surgery

15 16






17 18




Maximizing the Effectiveness of I-131 What are the two main things to do BEFORE I-131 administration that prepare the body to maximize the chance that I-131 will destroy target tissue (normal follicular and cancer cells)? What is the minimum value for TSH elevation? What are the two ways to get to this minimum TSH value and what are the potential negatives of each approach?

20



Two main things to do BEFORE I-131 administration that prepare the body to maximize the chance that I-131 will destroy target tissue (normal follicle and cancer cells) are: Elevate serum TSH > 30 mlU/mL (nl 0< 4.0) T4 deprivation (hypothyroid):
T4 has long half-life so need ~6 weeks off T4 to get TSH >30 In older adults, Hypo T4 is morbid and dangerous Two rhTSH (Thyrogen) injections (day -2 and -1):
- Not FDA approved in minors
- Need insurance or pay -\$1500
- Some experts say less effective than T4
deprivation for high-risk situations I use rhTSH prep in all risk cases in an adult with insurance coverage

21 22



<u>Postop serum Thyroglobulin (Tg)</u> is now a factor in deciding I-131 dose in most guidelines: rful to use postop Tg to determine I-131 dose if a substantial portion of no No. Normal follicular cells make Tg, which is why detectable Tg at any level after I-131 means residual cance What is the minimum number of weeks postop before checking Tg? 6 weeks because Tg has long half life in serum What is the threshold value of Tg that makes a decision about I-131 dose? < 1.0 vs ≥ 1.0 What does "suppressed" mean regarding postop Tg? Suppressed means TSH is low, say < 1.0 Current NCCN does not specify what TSH must be to invoke the < 1.0 postop Tg value as low risk of recurrence re does the level of Anti-Thyroglobulin Antibodies (TgAb) fit in the decision about I-131 dose? First, TgAbs block measurement of Tg by usual method so can't trust low Tg level if TgAb present Second, TgAb have the same meaning as Tg for tumor presence

23 24




TABLE 4. University of Florida Department of Radiation Oncology I-131 Dose Guidelines for DTC*†‡ No prior I-131 treatment and no visible residu Active surveillance§ (No I-131 treatment) If must be present: pTI-2, pN0-1a, M0 ≤3 positive nodes No ENE ≤1 positive node egative margin ostoperative Tg < 1.0 ng/mL|| If other Scenaria

If any are present:

p(T)S Stap muscle invasion

2-f positive nucle:


2-f positive nucles:

ENE that is not extensive!

Positive margin and postoperative Tg⁵ 2-1.0ng 100 mCi f any are present: pT4 Invasion of RLN, Trachea, Esophagus Extensive ENE¶ MI (with the exception of large-volume disease) 150-200 mCi Recurrent tumer beade only on seron they ophydalise for with a vivide, forces in throwing at least one prior \$1.33 treatment.


Recurrent tumer beade only on seron through the prior through the prior \$1.35 treatment to the prior \$1.35 treatment \$1.35 tre Visible Dx 150-200 mCi High Risk of micro residual dz after salvage surgery problems)
200 mCi is our standard dose when treating visible recurrent tumor - 150 mCi for high risk of micro residual dz following salvage surgery


26



The best "total thyroidectomy" is really a NEAR TOTAL Total body scan 7 days Salivary glands after 150 mCi I-131 Thyroid bed starburst

27 28





29 30

